TNF-Alpha's Influence on Depression & Inappetence

Meghna Chennoji Rao *

Nitte University Centre for Science Education and Research

* meghna.24bsbm@nitte.edu

Abstract

Tumor necrosis factor-alpha (TNF-alpha) plays a significant role in immune regulation and neurobiological processes associated with mood and behavior. This article explores the mechanisms by which TNF-alpha contributes to depressive symptoms and inappetence, including its impact on the HPA axis, neurotransmitter systems, metabolic hormones, and neuroinflammation.

Introduction

Tumor necrosis factor-alpha (TNF-alpha) initially gained attention for its role in tumor regression and immune defense. As a pro-inflammatory cytokine, TNF-alpha's influence extends beyond immune regulation and into neurobiological processes associated with mood and behavior [6]. This article explores the various mechanisms that may explain how TNF-alpha contributes to depressive symptoms and inappetence.

Mechanisms of TNF-Alpha Influence

The HPA axis is crucial for the body's response to stress. Stress activates the hypothalamus, particularly the paraventricular nucleus (PVN), which releases corticotropin-releasing hormone (CRH)—one of the factors why one might not feel hungry in the early hours of the day, leading to skipping breakfast. CRH stimulates the anterior pituitary gland to produce adrenocorticotropic hormone (ACTH), which then triggers the adrenal glands to release cortisol. Under normal conditions, cortisol provides negative feedback to limit continued activation of the HPA axis. However, high levels of TNF-alpha can disrupt this feedback loop [10]. When TNF-alpha is chronically elevated, the hypothalamus increases CRH release to manage perceived stress, leading to overproduction of cortisol. Elevated cortisol can then affect neurotransmitter systems like serotonin and dopamine [4]. CRH also suppresses appetite by reducing Neuropeptide Y (NPY) in the hypothalamus.

Tryptophan, the precursor to serotonin, can be diverted from serotonin production by inflammation. The enzyme indoleamine 2,3-dioxygenase (IDO), which is activated during inflammation, shunts tryptophan into the kynurenine pathway [11]. TNF-alpha is one of the cytokines that can increase IDO activity. This reduced availability of tryptophan for serotonin synthesis can lead to depressive-like symptoms, while certain kynurenine metabolites, such as quinolinic acid, 3-hydroxykynurenine, and 3-hydroxyanthranilic acid, are neurotoxic [8]. This shift in tryptophan metabolism is one potential mechanism through which TNF-alpha and other pro-inflammatory cytokines affect mood.

Microglia, the resident immune cells in the central nervous system, release pro-inflammatory mediators, including interleukin-1 beta (IL-1β), interleukin-6 (IL-6), and additional TNF-alpha when activated by TNF-alpha [1]. Prolonged activation of microglia results in neuroinflammation, which can disrupt synaptic plasticity by affecting *brain-derived neurotrophic factor (BDNF)*, a growth factor essential for neuronal survival and differentiation. Low levels of BDNF are often observed in depression [12]. Chronic inflammation also triggers oxidative stress and excitotoxicity, processes that are observed in neurodegenerative diseases, cerebrovascular accidents, and traumatic brain injury, further impairing brain function and mood regulation.

TNF-alpha is able to weaken the tight junctions between endothelial cells by altering proteins like occludin and claudin. [13] This increases Blood Brain Barrier (BBB) permeability, immune cells such as monocytes and lymphocytes infiltrate the CNS. These immune cells, along with TNF-alpha, trigger the activation of microglia, the brain's immune cells, leading to neuroinflammation.

TNF-alpha reduces the production of nitric oxide (No) by inhibiting endothelial nitric oxide synthase (ENOS) [9].This matters because NO is crucial for maintaining vascular tone and blood flow. Its reduction leads to impaired cerebral blood flow, contributing to cognitive decline and mood disorders.

TNF-alpha can alter the signaling of key neurotransmitters, including serotonin, dopamine, and glutamate [4]. By modifying their release, uptake, and receptor sensitivity, TNF-alpha destabilizes processes that are vital to motivation, reward, and emotional regulation:

- ***Serotonin:*** *TNF-alpha-induced inflammation reduces tryptophan levels and alters serotonin reuptake.*
- ***Dopamine:*** *Chronic inflammation may lower dopamine availability, influencing motivation and pleasure. The depletion of tetrahydrobiopterin (BH4), a cofactor required for dopamine synthesis by tyrosine hydroxylase, limits dopamine synthesis by reducing the conversion of tyrosine to L-DOPA.*
- ***Glutamate:*** *TNF-α and IL-1β impair astrocytic glutamate reuptake by downregulating EAAT expression and function, often through mechanisms like NF-κB activation and nitric oxide production [5]. Excessive glutamate activity due to inflammation can lead to excitotoxicity, which stresses neuronal circuits involved in cognitive and emotional processing.*

TNF-alpha also influences metabolic hormones like leptin and insulin [2]. Leptin is associated with satiety, and insulin is essential for regulating blood glucose levels. TNF-alpha binds to its receptors (TNFR1 or TNFR2) on adipocytes, activating signaling pathways like NF-κB, which upregulates the LEP gene responsible for leptin production. It also triggers the MAPK/ERK pathway, further enhancing gene expression and secretion.

TNF-alpha impairs the phosphorylation of insulin receptor substrate proteins, suppresses adiponectin production (which in turn affects insulin sensitivity), and increases circulating free fatty acids by stimulating lipolysis. Dysregulation of these hormones can disrupt appetite and energy balance, as seen in certain forms of depression.

Moreover, TNF-alpha affects neuropeptides in the hypothalamus that regulate hunger and energy expenditure. For instance, TNF-alpha decreases NPY expression (orexigenic — appetite inducing) and increases pro-opiomelanocortin (POMC)

expression [3].

POMC, a precursor to anorexigenic (appetite-suppressing) neuropeptides like α-MSH (melanocyte-stimulating hormone), activates melanocortin receptors (MC3R/MC4R) to suppress appetite.

TNF-alpha often coordinates with other cytokines like IL-1, IL-6, and interferon-gamma (IFN-γ). These cytokines amplify one another's effects, creating a network of feedback loops that sustain inflammation [6]. This network contributes to further disruptions in neurotransmission, HPA-axis balance, and metabolic regulation.

TNF-alpha inhibitors have been tested in treatment-resistant depression, but the results are mixed, suggesting that depression is multifactorial and involves other immune and non-immune pathways [7].

Discussion

While TNF-alpha's influence on the HPA axis, neurotransmitter systems, and neuroinflammation highlights its role in the pathology of mood disorders and appetite regulation, significant gaps in knowledge remain.

One such gap is individual susceptibility: why do some individuals with elevated TNF-alpha levels develop depression or cognitive decline, while others remain unaffected? Hypothetically, genetic polymorphisms in cytokine receptors, variations in stress exposure, and epigenetic factors might play a role. However, the specific interactions between these variables are not yet well understood.

Mechanistic details of TNF-alpha action are another area requiring further exploration. While its role in reducing nitric oxide (NO) production through endothelial nitric oxide synthase (eNOS) inhibition is well established, the precise signaling pathways and interactions with other molecular elements, such as reactive oxygen species (ROS) and vascular endothelial growth factor (VEGF), remain insufficiently studied.

Most studies offer a static view of TNF-alpha's effects. The temporal dynamics, how acute versus chronic elevations of TNF-alpha influence neural and behavioral outcomes, are poorly understood, presenting another critical area for future research.

References

1. C. Bufalino, N. Hepgul, E. Aguglia, and C. M. Pariante. The role of immune genes in the association between depression and inflammation: A review of recent clinical studies. *Brain Behavior and Immunity*, 31:31–47, 5 2012.

2. M. J. Carson, J. M. Doose, B. Melchior, C. D. Schmid, and C. C. Ploix. CNS immune privilege: hiding in plain sight. *Immunological Reviews*, 213(1):48–65, 9 2006.

3. I. A. Clark, L. M. Alleva, and B. Vissel. The roles of TNF in brain dysfunction and disease. *Pharmacology & Therapeutics*, 128(3):519–548, 9 2010.

4. R. Dantzer, J. C. O'Connor, G. G. Freund, R. W. Johnson, and K. W. Kelley. From inflammation to sickness and depression: when the immune system subjugates the brain. *Nature reviews. Neuroscience*, 9(1):46–56, 12 2007.

5. S. Hu, W. S. Sheng, L. C. Ehrlich, P. K. Peterson, and C. C. Chao. Cytokine effects on glutamate uptake by human astrocytes. *NeuroImmunoModulation*, 7(3):153–159, 1 2000.

6. A. H. Miller, V. Maletic, and C. L. Raison. Inflammation and its discontents: The role of cytokines in the pathophysiology of major Depression. *Biological Psychiatry*, 65(9):732–741, 1 2009.

7. C. L. Raison, R. E. Rutherford, B. J. Woolwine, C. Shuo, P. Schettler, D. F. Drake, E. Haroon, and A. H. Miller. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for Treatment-Resistant Depression. *JAMA Psychiatry*, 70(1):31, 9 2012.

8. R. Schwarcz, J. P. Bruno, P. J. Muchowski, and H.-Q. Wu. Kynurenines in the mammalian brain: when physiology meets pathology. *Nature reviews. Neuroscience*, 13(7):465–477, 6 2012.

9. S. Serafini, G. Ferretti, P. Monterosso, A. Angiolillo, A. Di Costanzo, and C. Matrone. TNF-α Levels Are Increased in Patients with Subjective Cognitive Impairment and Are Negatively Correlated with β Amyloid-42. *Antioxidants*, 13(2):216, 2 2024.

10. R. Smith. The macrophage theory of depression. *Medical Hypotheses*, 35(4):298–306, 8 1991.

11. M. C. Wichers and M. Maes. The role of indoleamine 2,3-dioxygenase (IDO) in the pathophysiology of interferon-alpha-induced depression. *PubMed*, 29(1):11–7, 1 2004.

12. R. Yirmiya, N. Rimmerman, and R. Reshef. Depression as a microglial disease. *Trends in Neurosciences*, 38(10):637–658, 10 2015.

13. B. V. Zlokovic. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. *Nature reviews. Neuroscience*, 12(12):723–738, 11 2011.

Word Counts

This section is *not* included in the word count.

Notes on Nature Methods Brief Communication

- Abstract: 3 sentences, 70 words.
- Main text: 3 pages, 2 figures, 1000-1500 words, more figures possible if under 3 pages

Statistics on word count

1 Something about something